文献速递基础与转化研究临床试验与 GCP新药、器械与细胞基因治疗研发

iPSC来源间充质干细胞治疗激素抵抗性急性移植物抗宿主病的I期多中心开放标签剂量递增研究:生产、安全性与疗效

Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study.
PubMed 文献 · Nat Med · 2020-09-14

该I期多中心开放标签剂量递增试验评估了iPSC来源间充质干细胞CYP-001治疗激素抵抗性急性GVHD的安全性和疗效。第100天客观缓解率86.7%、完全缓解率53.3%、总生存率86.7%。

要点

  • CYP-001在激素抵抗性急性GVHD中安全可耐受,无相关严重不良事件。
  • 第100天OR率86.7%、CR率53.3%、OS率86.7%。
  • iPSC来源MSC或可拓展至其他炎症与免疫介导疾病。

核心结论

  • CYP-001在激素抵抗性急性GVHD受试者中安全且耐受良好,未发生与CYP-001相关的严重不良事件。
  • 第100天OR率86.7%、CR率53.3%、OS率86.7%。
  • iPSC来源MSC的治疗应用现可拓展探索至多种炎症和免疫介导疾病。

研究设计与样本

  • I期、多中心、开放标签、剂量递增临床试验(NCT02923375)。
  • 队列B中1例在给药前退出并被排除分析。
  • 受试者在第0天和第7天接受CYP-001静脉输注。
  • 队列A剂量为1×10^6 cells/kg体重,每次输注最大1×10^8 cells;队列B剂量为2×10^6 cells/kg体重,每次输注最大2×10^8 cells。

主要发现

  • CYP-001安全且耐受良好,无与CYP-001相关的严重不良事件。
  • 第100天OR率为86.7%。
  • 第100天CR率为53.3%。
  • 第100天OS率为86.7%。

关键数值与推荐

  • 主要目标为评估CYP-001的安全性和耐受性。
  • 次要目标为基于第28/100天完全缓解、总体缓解和总生存的参与者比例评估疗效。
  • 队列A剂量:1×10^6 cells/kg体重,每次输注最大1×10^8 cells。
  • 队列B剂量:2×10^6 cells/kg体重,每次输注最大2×10^8 cells。

临床怎么用

  • CYP-001采用符合GMP的优化生产工艺制备,可应对传统MSC制造的可扩展性和供者间变异挑战。
  • 该I期结果支持在激素抵抗性急性GVHD中进一步探索iPSC来源MSC。
  • iPSC来源MSC的治疗应用可拓展至多种炎症和免疫介导疾病。

局限性

  • 为I期、开放标签、非对照、小样本研究(每组n=8,队列B 1例退出未分析)。
  • 主要目标为安全性和耐受性,疗效为次要目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The therapeutic potential of donor-derived mesenchymal stromal cells (MSCs) has been investigated in diverse diseases1, including steroid-resistant acute graft versus host disease (SR-aGvHD)2. However, conventional manufacturing approaches are hampered by challenges with scalability and interdonor variability, and clinical trials have shown inconsistent outcomes3,4. Induced pluripotent stem cells (iPSCs) have the potential to overcome these challenges, due to their capacity for multilineage differentiation and indefinite proliferation5,6. Nonetheless, human clinical trials of iPSC-derived cells have not previously been completed. CYP-001 (iPSC-derived MSCs) is produced using an optimized, good manufacturing practice (GMP)-compliant manufacturing process. We conducted a phase 1, open-label clinical trial (no. NCT02923375) in subjects with SR-aGvHD. Sixteen subjects were screened and sequentially assigned to cohort A or cohort B (n = 8 per group). One subject in cohort B withdrew before receiving CYP-001 and was excluded from analysis. All other subjects received intravenous infusions of CYP-001 on days 0 and 7, at a dose level of either 1 × 106 cells per kg body weight, to a maximum of 1 × 108 cells per infusion (cohort A), or 2 × 106 cells per kg body weight, to a maximum dose of 2 × 108 cells per infusion (cohort B). The primary objective was to assess the safety and tolerability of CYP-001, while the secondary objectives were to evaluate efficacy based on the proportion of participants who showed a complete response (CR), overall response (OR) and overall survival (OS) by days 28/100. CYP-001 was safe and well tolerated. No serious adverse events were assessed as related to CYP-001. OR, CR and OS rates by day 100 were 86.7, 53.3 and 86.7%, respectively. The therapeutic application of iPSC-derived MSCs may now be explored in diverse inflammatory and immune-mediated diseases.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Bloor AJC, Patel A, Griffin JE, et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat Med. 2020. PMID: 32929265. doi:10.1038/s41591-020-1050-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。